DOCS vs TTWO

Key Takeaways

• Doximity (DOCS) has endured a sharp sell-off in 2026, falling more than 50% year-to-date, driven by disappointing forward guidance, slowing revenue growth, and mounting AI-related investment costs that are compressing margins.
• Take-Two Interactive (TTWO) has shown relative resilience, with a modest single-digit decline year-to-date, supported by an 18% revenue expansion in fiscal 2026 and anticipation around the eventual release of Grand Theft Auto VI.
• DOCS trades at a significantly compressed valuation — a trailing P/E (price-to-earnings ratio) near 20 — reflecting market skepticism about its ability to monetize its AI pivot, while TTWO commands a forward P/E above 30 despite lingering GAAP (Generally Accepted Accounting Principles) losses.
• Both companies face distinct execution risks: DOCS contends with rising AI-native competition and soft pharma advertising budgets; TTWO remains unprofitable on a GAAP basis and carries high expectations around its flagship pipeline.
• The two stocks operate in entirely different sectors — healthcare technology versus interactive entertainment — making this comparison valuable for investors weighing defensive, cash-flow-rich businesses against growth narratives tied to blockbuster product cycles.

Introduction

Investors scanning the market in mid-2026 face starkly different propositions in Doximity and Take-Two Interactive. One is a niche healthcare platform grappling with an identity crisis as it pivots toward artificial intelligence; the other is a gaming giant riding a wave of revenue acceleration and towering expectations for its next marquee release. While their industries could hardly be more different, both stocks sit at pivotal junctures that demand clear-eyed analysis. This comparison is designed for traders and long-term investors who want to understand how two very different growth stories stack up in terms of momentum, valuation, risk, and sector dynamics.

DOCS Overview and Recent Performance

Doximity operates the largest professional medical network in the United States, used by more than 85% of U.S. physicians. The company generates revenue primarily through targeted pharmaceutical advertising and subscription-based workflow tools for hospitals and health systems. After years of robust double-digit growth, the narrative around DOCS has shifted dramatically in recent months. The stock has shed over half its value year-to-date, sliding from above $44 at the start of 2026 to around $21–$22 in recent trading, placing it near its 52-week low of $17.15.

The catalyst for the sell-off was Doximity's fiscal fourth-quarter 2026 earnings report, released in May, which delivered fiscal 2027 revenue guidance of $664 million to $676 million — implying just 3% to 5% year-over-year growth and landing well below Wall Street's consensus of roughly $697 million. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) guidance of $323 million to $335 million came in approximately 12% below Street estimates. Management framed fiscal 2027 as an "AI investment year," signaling elevated spending on compute costs, the DoxGPT clinical AI assistant, and brand marketing. More than ten Wall Street firms downgraded the stock or cut price targets in the immediate aftermath, and a CFO departure in April added to the uncertainty. Despite these headwinds, Doximity retains a pristine balance sheet — approximately $766 million in cash and equivalents with zero debt — and gross margins still hover near 89%.

TTWO Overview and Recent Performance

Take-Two Interactive Software is one of the world's largest video game publishers, home to iconic franchises including Grand Theft Auto, Red Dead Redemption, NBA 2K, and a growing mobile portfolio featuring titles such as Toon Blast and Match Factory. The company's fiscal 2026 revenue reached $6.66 billion, an 18.2% increase over the prior year, driven by strong recurrent consumer spending — which now accounts for roughly 79% of total net bookings — across its core live-service titles.

Shares of TTWO have held up comparatively well in 2026, declining approximately 7% to 8% year-to-date, with recent trading around the $237–$240 range. The stock has traded between a 52-week low of roughly $187 and a high near $266. Market sentiment has been supported by steady operational execution and the enormous shadow cast by Grand Theft Auto VI, widely expected to be one of the largest entertainment launches in history whenever it arrives. That said, Take-Two remains unprofitable on a GAAP basis — posting a fiscal 2026 diluted EPS of -$1.62, albeit a dramatic improvement from -$25.58 the prior year — and carries a forward P/E above 30, indicating that investors are pricing in significant future earnings expansion rather than current profitability.

Trending AI Robots

For traders seeking a data-driven edge in navigating cross-sector comparisons like DOCS and TTWO, Tickeron's Trending AI Robots page offers a curated window into algorithmic trading strategies. Tickeron hosts hundreds of AI-powered trading bots covering thousands of tickers, each with distinct trading styles, timeframes, and risk parameters. Only those bots demonstrating the strongest alignment with current market conditions earn a place in the Trending section. Many of these bots have shown annualized returns ranging from the high teens to over 40% in backtesting and real-money simulations, with trade-by-trade transparency and detailed performance statistics available for review. Whether you favor swing trading, trend following, or mean-reversion approaches, exploring these AI-driven strategies may complement your own comparative analysis.

Head-to-Head Comparison

From a sector perspective, Doximity and Take-Two occupy fundamentally different corners of the market. DOCS is a healthcare technology company tied to pharmaceutical advertising cycles and physician workflow tools; TTWO is a consumer discretionary entertainment business driven by game release cycles and live-service monetization. This divergence explains much of their recent performance gap.

On growth, TTWO holds the advantage. Take-Two's 18% top-line expansion in fiscal 2026 dwarfs Doximity's decelerating 13% revenue growth — and the forward outlook widens the gap further, with Doximity guiding to only 3%–5% growth in fiscal 2027 while Take-Two's pipeline, anchored by GTA VI, implies a far more robust trajectory. On profitability, however, Doximity remains firmly in the black with a trailing P/E around 20, whereas Take-Two continues to report GAAP net losses, making its premium forward multiple a bet on future earnings that have yet to materialize.

Risk profiles also differ sharply. DOCS faces competitive encroachment from AI-native platforms such as OpenEvidence, potential structural margin compression from AI compute spending, and softness in pharmaceutical advertising budgets. TTWO's risks center on execution: if GTA VI faces delays or fails to meet towering expectations, the stock's rich valuation could face a swift reassessment. On the stability front, Doximity's $766 million cash hoard and zero-debt balance sheet provide a downside cushion that Take-Two, with a net debt position exceeding $1 billion, does not enjoy in the same measure.

Tickeron AI Verdict

Based on observable trend consistency, relative momentum, and the presence of identifiable catalysts, Tickeron's AI-driven framework would likely tilt in favor of TTWO over DOCS under current market conditions. Take-Two benefits from a clearer near-term growth narrative — anchored by GTA VI anticipation and steadily expanding recurrent consumer spending — and its stock has maintained a more stable technical posture, holding above its 200-day moving average for much of recent market activity. Doximity, by contrast, remains in a pronounced downtrend with suppressed sentiment following a wave of analyst downgrades and limited near-term catalysts until its AI investments begin translating into measurable revenue acceleration. While Doximity's deeply discounted valuation and fortress balance sheet may appeal to value-oriented investors willing to wait, the AI's probabilistic assessment would favor the stock exhibiting stronger trend consistency and more defined upside catalysts at this juncture.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations